138 documents

Read All
23:05 , Dec 8, 2017 |  BioCentury  |  Finance

Negotiating NASH

New Enterprise Associates has signed onto Metacrine Inc.’s proposition that there is room to improve upon more advanced FXR agonists in development for non-alcoholic steatohepatitis. Metacrine closed an untranched $22 million series B round led...
Read More
07:00 , May 9, 2016 |  BioCentury  |  Product Development

Community organizers

With new papers published by the day and a flurry of big-dollar deals and financings, it's hard to separate the signal from the noise in the microbiome space. The space has become so hot that...
Read More
03:08 , Feb 3, 2016 |  BC Extra  |  Clinical News

Synthetic slides after dropping Trimesta for RRMS

Synthetic Biologics Inc. (NYSE-M:SYN) fell $0.21 (14%) to $1.28 on Tuesday after it said it terminated a license with the Regents of the University of California to IP covering the use of Trimesta, an oral...
Read More
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

SYN-010: Extension study data

Top-line data from 54 breath methane-positive IBS-C patients in the open-label extension of the double-blind, placebo-controlled, U.S. Phase II SB-2-010-001 trial showed that once-daily 42 mg oral SYN-010 met the primary endpoint of reducing breath...
Read More
08:00 , Dec 21, 2015 |  BC Week In Review  |  Clinical News

SYN-010: Phase II data

Top-line data from the double-blind, placebo-controlled, U.S. Phase II SB-2-010-001 trial in 63 breath methane-positive IBS-C patients showed that once-daily 42 mg oral SYN-010 significantly reduced the area under the curve (AUC) of breath methane...
Read More
07:00 , Oct 26, 2015 |  BC Week In Review  |  Clinical News

SYN-010: Phase II started

Synthetic began an open-label, U.S. Phase II extension trial to evaluate 42 mg oral SYN-010 once daily for about 2 months in about 60 patients who completed the Phase II SB-2-010-001 trial. Top-line data from...
Read More
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

SYN-010: Phase II started

Synthetic began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 21 and 42 mg oral SYN-010 once daily for 28 days in about 60 breath methane-positive patients. Synthetic is developing SYN-010 under section 505(b)(2)...
Read More
08:00 , Dec 4, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Ras/RAF/MEK/ERK pathway; Src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) Mouse studies suggest inhibiting ERK...
Read More
08:00 , Dec 16, 2013 |  BioCentury  |  Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
Read More
08:00 , Dec 5, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Leukemia-stroma coculture system to screen for selective inhibitors of leukemia stem cells (LSCs) A leukemia-stroma coculture system could...
Read More